J
Jerome B. Posner
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 205
Citations - 20577
Jerome B. Posner is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Paraneoplastic cerebellar degeneration. The author has an hindex of 73, co-authored 205 publications receiving 19833 citations.
Papers
More filters
Journal ArticleDOI
Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
TL;DR: It is concluded that vigorous treatment of leptomeningeal metastases with intrathecal chemotherapeutic agents improves symptomatology in some patients, and at times prolongs survival.
Journal ArticleDOI
Paraneoplastic Syndromes Involving the Nervous System
TL;DR: Paraneoplastic neurologic syndromes are incited by a tumor outside the nervous system that produces a characteristic antigen of the nervous System that damages nerve tissue and inhibits growth of the tumor.
Journal ArticleDOI
Radiation-induced dementia in patients cured of brain metastases.
TL;DR: It is believed that these fractionation schedules, several of which are used commonly, predispose to delayed neurologic toxicity, and that more protracted schedules should be employed for the safe and efficacious treatment of good-risk patients with brain metastases.
Journal ArticleDOI
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.
TL;DR: Patients with rapidly developing sensory neuropathy or symptoms of encephalomyelitis should be studied for the presence of the anti-Hu antibody; if the antibody is found, the possibility of small-cell lung cancer should be investigated.
Journal ArticleDOI
Clinical analysis of anti-Ma2-associated encephalitis.
Josep Dalmau,Francesc Graus,Alberto Villarejo,Jerome B. Posner,Deborah T. Blumenthal,Brian Thiessen,Albert Saiz,Patricio Meneses,Myrna R. Rosenfeld +8 more
TL;DR: Anti-Ma2 encephalitis (with or without anti-Ma1 antibodies) should be suspected in patients with limbic, diencephalic or brainstem dysfunction, MRI abnormalities in these regions, and inflammatory changes in the CSF.